

In the claims:

Please cancel the following claims:

Claim 1 (cancelled).
Claim 2 (cancelled).
Claim 3 (cancelled).
Claim 4 (cancelled).
Claim 5 (cancelled).
Claim 6 (cancelled).
Claim 7 (cancelled).
Claim 8 (cancelled).
Claim 9 (cancelled).
Claim 10 (cancelled).
Claim 11 (cancelled).
Claim 12 (cancelled).
Claim 13 (cancelled).
Claim 14 (cancelled).
Claim 15 (cancelled).
Claim 16 (cancelled).
Claim 17 (cancelled).
Claim 18 (cancelled).
Claim 19 (cancelled).
Claim 20 (cancelled).
Claim 21 (cancelled).
Claim 22 (cancelled).
Claim 28 (cancelled).
Claim 29 (cancelled).

Allowed claims:

23. (twice amended) A method of making at least one human autoantigenic fragment from at least one human autoantigen selected from the group consisting of human DNA-PK_{cs} and human NuMA, comprising the steps of

- (a) isolating cells containing at least one human autoantigen, and
- (b) contacting the cells with a lymphocyte granule enzyme to produce a mixture containing at least one human autoantigen fragment.

24. (amended) The method of claim 23 further comprising the step of (c) isolating said at least one human autoantigenic fragment.

25. (amended) The method of claim 23 wherein step (a) further comprises purifying at least one human autoantigen from the cells and step (b) comprises contacting said purified human autoantigen with granzyme B.

27. (amended) The method of claim 23 wherein said lymphocyte granule enzyme is isolated from the granules of at least one lymphocyte selected from the group consisting of cytotoxic T lymphocytes (CTL), natural killer cells (NK), lymphokine activated killer cells (LAK) and cells of the YT cell line.

30. The method of claim 23 wherein step (b) further comprises contacting the cells with a caspase inhibitor.